132 related articles for article (PubMed ID: 6725246)
1. Tangier disease. In vitro conversion of proapo-A-ITangier to mature APO-A-ITangier.
Bojanovski D; Gregg RE; Brewer HB
J Biol Chem; 1984 May; 259(10):6049-51. PubMed ID: 6725246
[TBL] [Abstract][Full Text] [Related]
2. Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins.
Schmitz G; Assmann G; Rall SC; Mahley RW
Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6081-5. PubMed ID: 6412234
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma.
Edelstein C; Gordon JI; Vergani CA; Catapano AL; Pietrini V; Scanu AM
J Clin Invest; 1984 Sep; 74(3):1098-103. PubMed ID: 6432845
[TBL] [Abstract][Full Text] [Related]
4. Human proapoA-ITangier: isolation of proapoA-ITangier and amino acid sequence of the propeptide.
Brewer HB; Fairwell T; Meng M; Kay L; Ronan R
Biochem Biophys Res Commun; 1983 Jun; 113(3):934-40. PubMed ID: 6409109
[TBL] [Abstract][Full Text] [Related]
5. Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).
Schaefer EJ; Kay LL; Zech LA; Brewer HB
J Clin Invest; 1982 Nov; 70(5):934-45. PubMed ID: 7130397
[TBL] [Abstract][Full Text] [Related]
6. Plasma apolipoproteins in Tangier disease, as studied with two-dimensional electrophoresis.
Visvikis S; Dumon MF; Steinmetz J; Manabe T; Galteau MM; Clerc M; Siest G
Clin Chem; 1987 Jan; 33(1):120-2. PubMed ID: 3100093
[TBL] [Abstract][Full Text] [Related]
7. In vivo conversion of recombinant human proapolipoprotein AI (rh-Met-proapo AI) to apolipoprotein AI in rabbits.
Saku K; Liu R; Ohkubo K; Bai H; Hirata K; Yamamoto K; Morimoto Y; Yamada K; Arakawa K
Biochim Biophys Acta; 1993 Apr; 1167(3):257-63. PubMed ID: 8481386
[TBL] [Abstract][Full Text] [Related]
8. Rat liver and small intestine produce proapolipoprotein A-I which is slowly processed to apolipoprotein A-I in the circulation.
Sliwkowski MB; Windmueller HG
J Biol Chem; 1984 May; 259(10):6459-65. PubMed ID: 6427215
[TBL] [Abstract][Full Text] [Related]
9. In vivo metabolism of proapolipoprotein A-I in Tangier disease.
Bojanovski D; Gregg RE; Zech LA; Meng MS; Bishop C; Ronan R; Brewer HB
J Clin Invest; 1987 Dec; 80(6):1742-7. PubMed ID: 3119665
[TBL] [Abstract][Full Text] [Related]
10. In vitro conversion of proapoprotein A-I to apoprotein A-I. Partial characterization of an extracellular enzyme activity.
Edelstein C; Gordon JI; Toscas K; Sims HF; Strauss AW; Scanu AM
J Biol Chem; 1983 Oct; 258(19):11430-3. PubMed ID: 6311811
[TBL] [Abstract][Full Text] [Related]
11. Abnormal apoprotein A-I isoprotein composition in patients with Tangier disease.
Zannis VI; Lees AM; Lees RS; Breslow JL
J Biol Chem; 1982 May; 257(9):4978-86. PubMed ID: 7068673
[No Abstract] [Full Text] [Related]
12. Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier).
Kay LL; Ronan R; Schaefer EJ; Brewer HB
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2485-9. PubMed ID: 6806810
[TBL] [Abstract][Full Text] [Related]
13. Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease).
Alaupovic P; Schaefer EJ; McConathy WJ; Fesmire JD; Brewer HB
Metabolism; 1981 Aug; 30(8):805-9. PubMed ID: 6790903
[TBL] [Abstract][Full Text] [Related]
14. Immunochemical study of the plasma low and high density lipoproteins in Tangier disease.
Dumon MF; Visvikis S; Manabe T; Clerc M
FEBS Lett; 1986 May; 201(1):163-7. PubMed ID: 3086124
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
Wang CS; Alaupovic P; Gregg RE; Brewer HB
Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of lipoproteins and apolipoproteins in serum of a Tangier patient by micro-scale two-dimensional electrophoresis.
Manabe T; Visvikis S; Dumon MF; Clerc M; Siest G
Clin Chem; 1987 Apr; 33(4):468-72. PubMed ID: 3103952
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins.
Schaefer EJ; Anderson DW; Zech LA; Lindgren FT; Bronzert TB; Rubalcaba EA; Brewer HB
J Lipid Res; 1981 Feb; 22(2):217-28. PubMed ID: 6787156
[TBL] [Abstract][Full Text] [Related]
18. Decreased proapolipoprotein A-I processing in liver disease: evidence for hepatic participation in proapolipoprotein A-I conversion.
Isobe H; Sakai H; Satoh M; Sakamoto S; Koga S; Nawata H
Clin Chim Acta; 1990 Aug; 189(3):303-11. PubMed ID: 2121392
[TBL] [Abstract][Full Text] [Related]
19. Tangier disease apolipoprotein A-I compared with normal plasma A-I using monoclonal antibodies.
Weech PK; Frohlich J; Marcel YL; N'Guyen TD; Milne RW
Biochim Biophys Acta; 1985 Jul; 835(2):402-7. PubMed ID: 2408675
[TBL] [Abstract][Full Text] [Related]
20. Properties of the plasma very low and low density lipoproteins in Tangier disease.
Heinen RJ; Herbert PN; Fredrickson DS
J Clin Invest; 1978 Jan; 61(1):120-32. PubMed ID: 201668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
